Grifols acquires Biotest's plasma collection centers for €220M to streamline plasma sourcing in Europe

- ***The acquisition supports Grifols' broader strategy to strengthen regional plasma sourcing and contribute to Europe's long-term plasma self-sufficiency, through more efficient management of existing collection network***
- ***Under a 30-year plasma supply agreement, Grifols will supply Biotest with plasma, supporting long-term supply continuity for its manufacturing operations***
- ***The transaction also includes all Biotest's European third-party plasma supply agreements, allowing Grifols to optimize plasma sourcing and capture efficiencies in procurement and supply chain management***
- ***The operation will allow Biotest's 47 plasma donation centers to be integrated into Grifols' existing European network, bringing the combined network to 97 sites across Germany, Austria, Hungary and the Czech Republic, under a single operating model that will enable more coordinated management of plasma collection across Europe***
- ***The consideration will be settled by offsetting against Biotest debt owed to Grifols***

Barcelona, Spain, November 27, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, has announced that it has acquired Biotest's European plasma collection business for €220 million by its subsidiary Grifols Worldwide Operations Ltd. The acquisition includes 14 collection centers in Germany, 19 in Hungary and 14 in the Czech Republic, consolidating management of Grifols' European collection network. The transaction also includes Biotest's European plasma supply contracts with third parties. This will allow the company to adjust its sourcing mix as production requirements change, coordinate procurement and logistics across the entire network, and streamline its engagement with regulatory authorities across European markets.

The operation will allow Biotest's 47 plasma donation centers to be integrated into Grifols' existing European network, bringing the combined network to 97 sites across Germany, Austria, Hungary and the Czech Republic. Through the integration of Biotest's plasma collection operations, Grifols expects to capture efficiencies by sharing operational best practices across its European network, adopting a more consistent approach to staffing, procurement and supply chain management, as well as optimizing its network of donation centers to improve collection productivity and optimize plasma cost per liter.

Grifols will manage plasma supply through two complementary agreements. Under a 30-year agreement, the company will supply Biotest with plasma, supporting greater predictability in plasma collection and manufacturing planning. The second agreement covers the plasma volumes under Biotest's existing contracts with third-party suppliers in Europe. Grifols will provide equivalent volumes for the remaining duration of those contracts.

Settled through the offset of intercompany debt, the acquisition reduces Biotest's leverage and secures its plasma supply for the next 30 years, while further strengthening its long-term partnership with Grifols. The transaction is expected to close on December 31, 2026, subject to the relevant regulatory approvals.

Strengthening the security of plasma supply in Europe

The integration of Biotest's collection operations is a further step in Grifols' long-term strategy of helping regions improve and secure their plasma supply. More than 300,000 patients in Europe depend on plasma-derived medicines to treat rare and chronic conditions, many of which have no alternative treatment options. As diagnosis improves, new therapeutic uses emerge and the population ages, demand for these medicines continues to grow.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's most diversified with more than 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 25,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non- voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com.

About Biotest

Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,800 employees worldwide. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).

MEDIA CONTACTS:

Grifols Press Office
media@grifols.com
Phone: +34 93 571 00 02

Biotest
pr@biotest.com

INVESTORS:

Investor Relations & Sustainability
investors@grifols.com – inversores@grifols.com
sustainability@grifols.com – sostenibilidad@grifols.com
Phone: +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the foreseeable impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.